Redhill Biopharma (Redhill Biopharma) Other Long Term Assets : $0.14 Mil (As of Jun. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Redhill Biopharma Other Long Term Assets?

Redhill Biopharma's other long-term assets for the quarter that ended in Jun. 2023 was $0.14 Mil.

Redhill Biopharma's quarterly other long-term assets declined from Dec. 2022 ($0.15 Mil) to Mar. 2023 ($0.15 Mil) but then stayed the same from Mar. 2023 ($0.15 Mil) to Jun. 2023 ($0.14 Mil).

Redhill Biopharma's annual other long-term assets declined from Dec. 2021 ($16.17 Mil) to Dec. 2022 ($0.15 Mil) and declined from Dec. 2022 ($0.15 Mil) to Dec. 2023 ($0.15 Mil).

Redhill Biopharma Other Long Term Assets Historical Data

The historical data trend for Redhill Biopharma's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma Other Long Term Assets Chart

Redhill Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long Term Assets

Get a 7-Day Free Trial

0.15

16.16

16.17

0.15

Redhill Biopharma Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23
Other Long Term Assets	Get a 7-Day Free Trial															0.15	0.15	0.15	0.14	0.15

Redhill Biopharma Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Redhill Biopharma (Redhill Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (NAS:RDHL) » Definitions » Other Long Term Assets

Comparable Companies

Traded in Other Exchanges

2RH0:Germany 2RH0:Germany

Address

21 Ha’arba’a Street, Tel Aviv, ISR, 6473921

Website

https://www.redhillbio.com

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.